الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 197 |  |  |
| | | from | 197 | | |
Abstract
Cerebrovascular stroke is one of the leading causes of death and
disability in the world. According to WHO, stroke is second leading
cause of death after ischemic heart disease in high and middle income
countries while sixth leading cause of death in low income countries
(Pappachan and Kirkham, 2008).
One biochemical marker, ischemia-modified albumin (IMA),
has been widely studied in tissue ischemia in recent years. IMA
appears to be an early indicator of myocardial ischemia, which is
detectable before the occurrence of myocardial infarction. Moreover,
serum IMA increases in mesenteric thrombosis, pulmonary embolism,
stroke and other ischemic diseases. Thus, in addition to being a
predictor of myocardial infarction, IMA may be a useful marker for
ACVD (Sbarouni et al., 2008).
Fibulin-5 is a multicellular glycoprotein, belonging to fibulin
family which has 7 members (Hu et al., 2016). Compared with other
fibulins, it has a unique arginine-glycine-aspartic acid (RGD) domain
in the N-terminal region that mediates binding to integrins (Hu et al.,
2011).
The aim of this study was to evaluate the role of ischemia
modified albumin (IMA) and fibulin 5 in the differentiation between
ischemic and hemorrhagic cerebrovascular stroke, and their
relationships with the severity and prognosis in patients with acute
cerebrovascular disease.